Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 13/20 | 0.45 |
| ▸ | EGFR | P00533 | 4/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | FECH | P22830 | 1/20 | 0.45 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.45 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29887966 | 1.00 | ERBB2 (0.45) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24569736 | 0.86 | ERBB2 (0.48) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL29888070 | 0.86 | ERBB2 (0.48) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24569439 | 0.85 | ERBB2 (0.61) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL29888085 | 0.85 | ERBB2 (0.58) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL29887854 | 0.85 | ERBB2 (0.61) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL29888106 | 0.85 | ERBB2 (0.61) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24569501 | 0.85 | ERBB2 (0.58) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24569898 | 0.83 | ERBB2 (0.48) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL29888307 | 0.83 | ERBB2 (0.48) | ERBB2EGFRNQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |